Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study
Tóm tắt
The success of tuberculosis treatment relies on patients adhering to their medication regimen consistently. However, adherence levels tend to decrease among patients who experience adverse drug reactions to antitubercular medications, leading to suboptimal treatment outcomes. Hence, this study aimed to examine the types, incidence rates, and severity of adverse reactions caused by first-line antitubercular drugs. Additionally, it aimed to identify factors associated with the development of these reactions. By doing so, the study aimed to facilitate the provision of personalized and effective treatment to patients, ultimately improving treatment outcomes. Newly diagnosed patients with active tuberculosis were monitored from the start of their treatment until the completion of therapy. Any adverse reactions to anti-TB drugs that they encountered were carefully recorded. The collected data were analyzed using appropriate statistical methods such as analysis of variance, Chi-squared test, Fisher's exact test, and independent t-tests. Logistic regression was employed to assess the association between adverse drug reactions and various socio-demographic and clinical factors of the patients, using odds ratios as a measure of association. Among the 378 patients included in the study, 181 individuals (47.9%) reported experiencing at least one adverse drug reaction, with an incidence rate of 1.75 events per 100-person months. The majority of these reactions occurred during the intensive phase of treatment. The gastrointestinal tract was the most commonly affected system, followed by the nervous system and skin. Patients aged over 45 years (OR = 1.55, 95% CI 1.01–2.39, p = 0.046) and those with extrapulmonary tuberculosis (OR = 2.41, 95% CI 1.03–5.64) were more likely to develop gastrointestinal reactions. Female gender was a significant predictor of both skin (OR = 1.78, 95% CI 1.05–3.02, p = 0.032) and nervous system (OR = 1.65, 95% CI 1.07–2.55, p = 0.024) reactions. Additionally, alcohol use and HIV infection were identified as independent predictors of adverse drug reactions affecting all three systems. Significant risk factors for developing antitubercular drug adverse reactions include alcohol consumption, cigarette smoking, being HIV positive, female gender and extrapulmonary tuberculosis.
Tài liệu tham khảo
Gupta R, Lucas S, Fielding K, Lawn S. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in a resource-limited setting: a systematic review and meta-analysis. AIDS. 2015;29:1987–2002.
Luetkemeyer A. Tuberculosis and HIV. HIV InSite 2013. http://hivinsite.ucsf.edu/InSite?page=kb-05-01-06#S2X. Accessed Jan 28 2019.
MOH. The National Tuberculosis Health Sector Strategic Plan for Ghana: 2015–2020. Ministry of Health 2015:1–132.
WHO. Global Tuberculosis Report 2020. Geneva: 2020.
Pablos-Méndez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med. 1997;102:164–70. https://doi.org/10.1016/s0002-9343(96)00402-0.
Boateng S, Kodama T, Tachibana T, Hyoi N. Factors contributing to Tuberculosis (TB) defaulter rate in New Juaben Municipality in the Eastern Region of Ghana. J Natl Inst Public Health. 2010;59:291–7.
Danso E, Addo IY, Ampomah IG. Patients’ compliance with tuberculosis medication in Ghana: evidence from a Periurban community. Adv Public Health. 2015;2015:948487. https://doi.org/10.1155/2015/948487.
Chen X, Du L, Wu R, Xu J, Ji H, Zhang Y, et al. The effects of family, society and national policy support on treatment adherence among newly diagnosed tuberculosis patients: a cross-sectional study. BMC Infect Dis. 2020;20:623. https://doi.org/10.1186/s12879-020-05354-3.
Zegeye A, Dessie G, Wagnew F, Gebrie A, Islam SMS, Tesfaye B, et al. Prevalence and determinants of anti-tuberculosis treatment non-adherence in Ethiopia: a systematic review and meta-analysis. PLoS ONE. 2019;14:1–15. https://doi.org/10.1371/journal.pone.0210422.
Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest. 1979;76:741–3. https://doi.org/10.1378/chest.76.6_supplement.741.
Mason JO. Opportunities for the elimination of tuberculosis. Am Rev Respir Dis. 1986;134:201–3. https://doi.org/10.1164/arrd.1986.134.2.201.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.
Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140:795–801.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–32.
Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7. https://doi.org/10.1164/rccm.200206-626OC.
Gholami K, Kamali E, Hajiabdolbaghi M, Shalviri G. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract (Granada). 2006;4:134–8.
Konuru V, Venkateswarlu K, Tiwari K. Study of adverse drug reactions in tuberculosis patients. J Pharma Res. 2017;6:61–5.
Chung SJ, Byeon SJ, Choi JH. Analysis of adverse drug reactions to first-line anti-tuberculosis drugs using the Korea adverse event reporting system. J Korean Med Sci. 2022. https://doi.org/10.3346/jkms.2022.37.e128.
Sant’Anna FM, Araújo-Pereira M, Schmaltz CAS, Arriaga MB, de Oliveira RVC, Andrade BB, et al. Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study. Front Trop Dis. 2022. https://doi.org/10.3389/fitd.2021.748310.
Benedetti MS, Dostert P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect. 1994;102:101–5.
Kurniawati F, AzharSyedSulaiman S, Wasif Gilani S. Adverse drug reactions of primary anti-tuberculosis drugs among tuberculosis patients treated in chest clinic. Int J of Pharm Life Sci. 2012;3:1331–8.
Khayyam KU, Imam F, Sharma M, Pillai KK, Behera D. Pyrazinamide-induced maculopapular rash. Indian J Dermatol. 2010;55:384. https://doi.org/10.4103/0019-5154.74562.
Shenoy A, Chowta M, Gadgade A, Jha A, Ramapuram J. Evaluation of adverse drug reactions in HIV positive patients in a tertiary care hospital. Perspect Clin Res. 2015;6:34. https://doi.org/10.4103/2229-3485.148808.
Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med. 1984;101:92–104. https://doi.org/10.7326/0003-4819-101-1-92.
Aouam K, Chaabane A, Loussaïef C, ben Romdhane F, Boughattas NA, Chakroun M. Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management. Med Mal Infect. 2007;37:253–61. https://doi.org/10.1016/J.MEDMAL.2006.12.006.
Vilholm OJ, Christensen AA, Zedan AH, Itani M. Drug-induced peripheral neuropathy. Basic Clin Pharmacol Toxicol. 2014;115:185–92.
Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980;61:191–6.
Onder G, Landi F, della Vedova C, Atkinson H, Pedone C, Cesari M, et al. Moderate alcohol consumption and adverse drug reactions among older adults. Pharmacoepidemiol Drug Saf. 2002;11:385–92. https://doi.org/10.1002/PDS.721.
Fraser AG. Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet. 1997;33:79–90.
Moore AA, Whiteman EJ, Ward KT. Risks of combined alcohol/medication use in older adults. Am J Geriatr Pharmacother. 2007;5:64–74.
Baciewicz AM. Isoniazid interactions. South Med J. 1985;78:714–8.
NHS. Drink less - Better Health - NHS 2022. https://www.nhs.uk/better-health/drink-less/.
Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of tuberculosis treatment. Clin Dev Immunol. 2011. https://doi.org/10.1155/2011/103917.
Michael OS, Sogaolu OM, Fehintola FA, Ige OM, Falade CO. Adverse events to first-line anti-tuberculosis drugs in patients co-infected with HIV and tuberculosis. Ann Ibd Pg Med. 2016;14:21–9.
Breen RAM, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791–4. https://doi.org/10.1136/thx.2006.058867.
Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4:e4439. https://doi.org/10.1371/journal.pone.0004439.
Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9. https://doi.org/10.1136/bmj.329.7456.15.
Cunningham G, Dodd TRR, Grant DJ, Mcmurdo MEI, Michael R, Richards E. Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age Ageing. 1997;26:375–82.
Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x.
de Vries ST, Denig P, Ekhart C, Burgers JS, Kleefstra N, Mol PGM, et al. Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: an explorative observational study. Br J Clin Pharmacol. 2019;85:1507–15.
Yu Y, Chen J, Li D, Wang L, Wang W, Liu H. Systematic analysis of adverse event reports for sex differences in adverse drug events. Sci Rep. 2016;6:1–9.
Castellana E, Chiappetta MR, Cattel F. Gender differences and pharmacovigilance: analysis in the Italian population. Ital J Gender-Specific Med. 2018;4:27–33.
Montastruc J-L, Lapeyre-Mestre M, Bagheri H, Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol. 2002;16:343–6. https://doi.org/10.1046/j.1472-8206.2002.00100.x.
Sinha K, Marak IT, Singh W. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. J Assoc Chest Phys. 2013. https://doi.org/10.4103/2320-8775.123213.
Gustafson P. Gender differences in risk perception: theoretical and methodological perspectives. Risk Anal. 1998. https://doi.org/10.1023/B:RIAN.0000005926.03250.c0.
Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis. 2002;6:942–51.
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nuñez-Garbin A, et al. Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima. Peru PLoS One. 2011;6:1–5. https://doi.org/10.1371/journal.pone.0027610.
Ma Y, Che N-Y, Liu Y-H, Shu W, Du J, Xie S-H, et al. The joint impact of smoking plus alcohol drinking on treatment of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis. 2019;38:651–7. https://doi.org/10.1007/s10096-019-03489-z.
Baker CL, Flores NM, Zou KH, Bruno M, Harrison VJ. Benefits of quitting smoking on work productivity and activity impairment in the United States, the European Union and China. Int J Clin Pract. 2017;71:1–10. https://doi.org/10.1111/ijcp.12900.
Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, et al. Quitting smoking will benefit your health: the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res. 2014;20:301–9. https://doi.org/10.1158/1078-0432.CCR-13-2261.
Lorent N, Sebatunzi O, Mukeshimana G, van den Ende J, Clerinx J. Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. PLoS ONE. 2011;6:e19566. https://doi.org/10.1371/JOURNAL.PONE.0019566.